Canakinumab

Generic Name
Canakinumab
Brand Names
Ilaris
Drug Type
Biotech
Chemical Formula
-
CAS Number
914613-48-2
Unique Ingredient Identifier
37CQ2C7X93
Background

Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain ...

Indication

Canakinumab is indicated for the treatment of periodic fever syndromes in specific patient populations. In patients ≥4 years of age, canakinumab is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). In adult and pediatric patients, canakinum...

Associated Conditions
Adult Onset Still's Disease, Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflammatory Syndrome (FCAS), Familial Mediterranean Fever (FMF ), Gout Flares, Mevalonate Kinase Deficiency, Muckle-Wells Syndrome (MWS), Systemic Juvenile Idiopathic Arthritis (SJIA), Tumour necrosis factor receptor-associated periodic syndrome
Associated Therapies
-
Clinical Trials
Related News

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

First Posted Date
2017-02-27
Last Posted Date
2022-08-15
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
111
Registration Number
NCT03064854
Locations
🇺🇸

UCLA Santa Monica Hematology / Oncology SC-2, Santa Monica, California, United States

🇺🇸

Henry Ford Health System SC, Detroit, Michigan, United States

🇺🇸

Stanford Cancer Center SC, Stanford, California, United States

and more 3 locations

Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease

Phase 2
Withdrawn
Conditions
Kawasaki Disease
Interventions
Drug: Canakinumab
First Posted Date
2016-12-02
Last Posted Date
2017-02-17
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT02980263

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Phase 2
Completed
Conditions
Sickle Cell Anemia
Interventions
Drug: Placebo
Drug: ACZ885
First Posted Date
2016-11-10
Last Posted Date
2021-10-11
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
49
Registration Number
NCT02961218
Locations
🇬🇧

Novartis Investigative Site, London, United Kingdom

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

Phase 2
Completed
Conditions
Pulmonary Sarcoidosis
Interventions
Drug: ACZ885
Drug: Placebo
First Posted Date
2016-09-02
Last Posted Date
2021-10-04
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
40
Registration Number
NCT02888080
Locations
🇳🇱

Novartis Investigative Site, Rotterdam, Netherlands

Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA)

Phase 1
Conditions
Periodic Fever
Interventions
Drug: Canakinumab
First Posted Date
2016-05-18
Last Posted Date
2018-09-04
Lead Sponsor
Rabin Medical Center
Target Recruit Count
10
Registration Number
NCT02775994
Locations
🇮🇱

SCMCI, Petah tikva, Israel

1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement

Phase 2
Completed
Conditions
Behcet Disease
Interventions
Drug: Canakinumab
First Posted Date
2016-04-29
Last Posted Date
2020-06-11
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
8
Registration Number
NCT02756650
Locations
🇹🇷

Novartis Investigative Site, Istanbul, Turkey

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

First Posted Date
2015-01-08
Last Posted Date
2020-05-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
31
Registration Number
NCT02334748
Locations
🇫🇷

Novartis Investigative Site, Paris, France

Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk

Phase 2
Completed
Conditions
HIV
Cardiovascular Disease
Interventions
Drug: Placebo
Drug: Canakinumab
First Posted Date
2014-10-23
Last Posted Date
2023-04-20
Lead Sponsor
Priscilla Hsue, MD
Target Recruit Count
43
Registration Number
NCT02272946
Locations
🇺🇸

San Francisco General Hospital, San Francisco, California, United States

Canakinumab for Treatment of Adult-onset Still's Disease

Phase 2
Terminated
Conditions
Adult-Onset Still´s Disease
Interventions
Drug: Canakinumab
Drug: Placebo
First Posted Date
2014-07-30
Last Posted Date
2020-08-07
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
36
Registration Number
NCT02204293
Locations
🇩🇪

Immanuel Krankenhaus Berlin, Berlin, Germany

🇩🇪

Universität Erlangen, Erlangen, Germany

🇩🇪

Charité Campus Mitte, Berlin, Germany

and more 11 locations

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Phase 3
Completed
Conditions
Hereditary Periodic Fevers
Interventions
Drug: Placebo
Drug: Canakinumab
First Posted Date
2014-02-11
Last Posted Date
2018-05-17
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
203
Registration Number
NCT02059291
Locations
🇬🇧

Novartis Investigative Site, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy